DOI: https://doi.org/10.22263/2312-4156.2022.3.9
M.A. Katina
Modern approaches to vitiligo treatment
Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus
Vestnik VGMU. 2022;21(3):9-16.
Abstract.
Vitiligo is an acquired hypomelanosis with an occurrence frequency of 0.1%-2% among adults and children worldwide. Currently, vitiligo is considered as a multifactorial disease associated with genetic factors, environmental factors, autoimmune mechanisms, oxidative stress and a destruction of melanogenesis with the formation of clearly defined hypopigmented macules on the skin. According to the modern classification, vitiligo is divided into two main forms: non-segmental and segmental. To facilitate the diagnosis of vitiligo, Wood’s lamp, dermatoscopy, histopathological examination can be used. The choice of vitiligo therapy depends on the activity of the process, the skin phototype, prevalence and the clinical form of the disease. The basis of vitiligo therapy is topical agents, suppressing an inflammation: topical steroids, calcineurin inhibitors, JAK inhibitors; phototherapy, which is used to stimulate melanogenesis. The given article reviews the indications and effectiveness of various methods of vitiligo treatment, new approaches included.
Keywords: vitiligo, pathogenesis, topical therapy, phototherapy.
References
1. Bergqvist C, Ezzedine K. Vitiligo: A focus on pathogenesis and its therapeutic implications. J Dermatol. 2021 Mar;48(3):252-70. doi: http://doi.org/10.1111/1346-8138.15743
2. Konieczna A, Winnicki A, Krysiński J. New perspectives in vitiligo treatment. Farmacja Polska. 2020 Jul;76(6):324-32. doi: http://doi.org/10.32383/farmpol/125553
3. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: A comprehensive overview. J Am Acad Dermatol. 2011 Sep;65(3):473-91. doi: http://doi.org/10.1016/j.jaad.2010.11.061
4. Mohammed GF, Gomaa AH, Al-Dhubaibi MS. Highlights in pathogenesis of vitiligo. World J Clin Cases. 2015 Mar;3(3):221-30. doi: http://doi.org/10.12998/wjcc.v3.i3.221
5. Kruglova LS. Vitiligo: current views on etiology, pathogenesis, and therapy methods. Ros Zhurn Kozh Venerol Boleznei. 2016;19(4):241-4. (In Russ.) doi: http://doi.org/10.18821/1560-9588-2016-19-4-241-244
6. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015 Jul;386(9988):74-84. doi: http://doi.org/10.1016/S0140-6736(14)60763-7
7. Errichetti E, Stinco G. Dermoscopy in General Dermatology: A Practical Overview. Dermatol Ther (Heidelb). 2016 Dec;6(4):471-507. doi: http://doi.org/10.1007/s13555-016-0141-6
8. Calonje E, Brenn T, Lazar A, McKee PH. Мckee`s pathology of the skin: with clinical correlations. 4th ed. Elsevier Saunders; 2012. 1803 p.
9. Whitton M, Pinart M, Batchelor JM, Leonardi-Bee J, Gonzalez U, Jiyad Z, et al. Evidence-based management of vitiligo: summary of a Cochrane systematic review. Br J Dermatol. 2016 May;174(5):962-9. doi: http://doi.org/10.1111/bjd.14356
10. Lee JH, Kwon HS, Jung HM, Lee H, Kim GM, Yim HW, et al. Treatment Outcomes of Topical Calcineurin Inhibitor Therapy for Patients With Vitiligo A Systematic Review and Meta-analysis. JAMA Dermatol. 2019 Aug;155(8):929-38. doi: http://doi.org/10.1001/jamadermatol.2019.0696
11. Mohammad TF, Al-Jamal M, Hamzavi IH, Harris JE, Leone G, Cabrera R, et al. The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo. J Am Acad Dermatol. 2017 May;76(5):879-888. doi: http://doi.org/10.1016/j.jaad.2016.12.041
12. Sach TH, Thomas KS, Batchelor JM, Perways A, Chalmers JR, Haines RH, et al. An economic evaluation of the randomised controlled trial of topical corticosteroid and home-based narrowband UVB for active and limited vitiligo (The HI-Light Trial). Br J Dermatol. 2021 May;184(5):840-8. doi: http://doi.org/10.1111/bjd.19554
13. Dang Y-P, Li Q, Shi F, Yuan X-Y, Liu W. Effect of topical calcineurin inhibitors as monotherapy or combined with phototherapy for vitiligo treatment: a meta-analysis. Dermatol Ther. 2016 Mar-Apr;29(2):126-33. doi: http://doi.org/10.1111/dth.12295
14. Bae JM, Jeong K-H, Choi CW, Park JH, Lee HJ, Kim HJ, et al. Development of evidence-based consensus on critical issues in the management of patients with vitiligo: A modified Delphi study. Photodermatol Photoimmunol Photomed. 2021 Jan;37(1):3-11. doi: http://doi.org/10.1111/phpp.12598
15. Rothstein B, Joshipura D, Saraiya A, Abdat R, Ashkar H, Turkowski Y, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol. 2017 Jun;76(6):1054-60. doi: http://doi.org/10.1016/j.jaad.2017.02.049
16. Cotter C, Ferguson J. Ruxolitinib cream for the treatment of vitiligo: a randomised, controlled, phase 2 trial: a critical appraisal. Br J Dermatol. 2021 May;184(5):826-7. doi: http://doi.org/10.1111/bjd.19674. Epub 2021 Jan 4.
17. Kanokrungsee S, Rajatanavin N. Clinical outcomes of topical bimatoprost for non segmental facial vitiligo: a preliminary study. J Cosmetic Dermatol. 2021 Mar;20(3):812-8. doi: http://doi.org/10.1111/jocd.13648
18. Tovar-Garza A, Hinojosa JA, Hynan LS, Pandya AG. Addition of oral minipulse dexamethasone to narrowband ultraviolet B phototherapy and topical steroids helps arrest disease activity in patients with vitiligo. Br J Dermatol. 2019 Jan;180(1):193-4. doi: http://doi.org/10.1111/bjd.17150
19. Garza-Mayers AC, Kroshinsky D. Low-dose Methotrexate for Vitiligo. Drugs Dermatol. 2017 Jul;16(7):705-6.
20. Singh H, Kumaran MS, Bains A, Parsad D. A Randomized Comparative Study of Oral Corticosteroid Minipulse and Low-Dose Oral Methotrexate in the Treatment of Unstable Vitiligo. Dermatology. 2015;231(3):286-90. doi: http://doi.org/10.1159/000433424
21. Bishnoi A, Vinay K, Kumaran MS, Parsad D. Oral mycophenolatemofetil as a stabilizing treatment for progressive non-segmental vitiligo: results from a prospective, randomized, investigator-blinded pilot study. Arch Dermatol Res. 2021 Jul;313(5):357-65. doi: http://doi.org/10.1007/s00403-020-02108-8
22. Grimes PE, Hamzavi I, Lebwohl M, Ortonne JP, Lim HW. The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. JAMA Dermatol. 2013 Jan;149(1):68-73. doi: http://doi.org/10.1001/2013.jamadermatol.386
23. Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015 Jan;151(1):42-50. doi: http://doi.org/10.1001/jamadermatol.2014.1875
24. Gamal AM, Rasha A, Moftah NH. Updates in surgical treatment of vitiligo. JRAM. 2021 Jan;2(1):118-27. doi: http://doi.org/10.21608/jram.2020.44431.1086
25. Daniel BS, Wittal R. Vitiligo treatment update. Australas J Dermatol. 2015 May;56(2):85-92. doi: http://doi.org/10.1111/ajd.12256
Information about authors:
M.A. Katina – Candidate of Medical Sciences, associate professor of the Chair of Dermatovenerology & Cosmetology, Vitebsk State Order of Peoples’ Friendship Medical University,
E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Mariya A. Katina.
